This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study


Wroolie, T. E., Kenna, H. A., Williams, K. E., Powers, B. N., Holcomb, M., Lazzeroni, L., Rasgon, N. L.


Acta Neurologica Scandinavica, Volume: 119, No.: 3, Pages.: 172-179

Year of Publication



Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center for Neuroscience in Women’s Health, Stanford University School of Medicine. Neuropsychological data were collected on 22 community-dwelling postmenopausal women (11 apoE-epsilon4 carriers and 11 apoE-epsilon4 non-carriers) with at least one putative risk factor for AD.; Results: ApoE-epsilon4 status was not a significant predictor of change in neuropsychological performance. Changes associated with memantine treatment for entire sample included significant declines in some variables associated with verbal learning and memory that improved upon medication withdrawal. A positive medication effect was noted with executive functions and possibly category fluency. Trend-level improvements were seen in motor dexterity of the non-dominant hand and maintained even after drug discontinuance.; Conclusions: Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD. ApoE-epsilon4 carrier status did not account for observed changes in cognition.;

Bibtex Citation

@article{Wroolie_2009, doi = {10.1111/j.1600-0404.2008.01084.x}, url = {}, year = 2009, month = {mar}, publisher = {Wiley-Blackwell}, volume = {119}, number = {3}, pages = {172--179}, author = {T. E. Wroolie and H. A. Kenna and K. E. Williams and B. N. Powers and M. Holcomb and L. Lazzeroni and N. L. Rasgon}, title = {Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study}, journal = {Acta Neurologica Scandinavica} }


aged, alzheimer disease, apolipoprotein e4, cognition, dementia, drug effects, epidemiology, excitatory amino acid antagonists, female, genetic predisposition to disease, genetics, humans, hypothyroidism, memantine, memory disorders, meopausal, middle aged, mood disorders, neuropsychological tests, nootropic agents, pharmacology, pilot projects, post, postmenopause, prevention & control, prospective studies, risk, therapeutic use, treatment outcome, women

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Case Control Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions, Risk Factor Modification

Risk Factor Modifications

At risk population

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime